<< Biology of lung cancer varies by age and gender | FoP in patients with chronic arthritis or cancer: Group psychotherapy may help >>
Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Norsk | Русский | Svenska | Polski

Continua Certified USB-enabled platform now available for building agent healthcare devices

Published on February 10, 2010 at 4:43 AM · No Comments

Texas Instruments Incorporated (TI) (NYSE: TXN) and S3 Group, a connected healthcare technology solutions company, today announced the availability of the first Continua Certified™ USB-enabled platform for building agent healthcare devices. The platform consists of TI's ultra-low power MSP430 microcontroller (MCU) and S3 Group's Embedded Agent Stack (EAS) – an 11073 PAN device (agent) stack, which has been optimized for resource constrained platforms. The platform for agent devices will enable original equipment manufacturers (OEMs) to bring personal health devices to market quicker and easier. Both TI and S3 Group are members of the Continua Health Alliance, a non-profit, open industry organization of healthcare and technology companies joined together to establish a system of interoperable personal telehealth solutions to better manage health and wellness. This new platform will help developers improve the quality and accessibility of healthcare by simplifying the design of USB-enabled consumer medical products such as blood glucose meters, digital thermometers, pulse oximeters and blood pressure monitors.

"S3 Group has been at the forefront of devising ways to leverage the latest technology to enable faster delivery of telehealth for years, and we are very proud to have been selected by TI for the development of this Continua Certified™ platform for device manufacturers," John Mulcahy, general manager, telehealth, S3 Group.

Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.



  Country flag

biuquote
  • Comment
  • Preview
Loading